Clinical Trial Update: Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating Niraparib as neoadjuvant therapy for breast cancer showed antitumor activity and assessed safety; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Niraparib (Niraparib)

Snippet

Sponsor: Tesaro, Inc. | Conditions: Neoplasms, Breast | Phase 1 | Status: COMPLETED | Results posted: 2021-01-12